Hemostasis Today

September, 2026
September 2026
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Gevorg Yaghjyan: Low Drug Levels, Higher Cardiovascular Risk in Lupus
Sep 25, 2026, 13:32

Gevorg Yaghjyan: Low Drug Levels, Higher Cardiovascular Risk in Lupus

Gevorg Yaghjyan, Adviser at Intelligent Medical Cloud, Co-Founder of ICPD, shared a post on LinkedIn about a recent article by Rachel Martin, published in Yale School of Medicine, adding:

“Beyond Efficacy: Why Medication Adherence and Drug Exposure Matter in Clinical Development

An important Yale-led study highlights how a well-established therapy may provide benefits beyond controlling the primary disease.

Researchers followed 248 patients with systemic lupus erythematosus and found that very low blood levels of hydroxychloroquine – together with poor medication adherencee – were associated with increased cardiovascular risk over one to two years.

The findings support therapeutic drug monitoring and more individualized dosing strategies rather than a uniform, one-size-fits-all approach.

From a clinical-trial and drug-development perspective, this study reinforces several important principles:

  • Clinical outcomes depend not only on the prescribed dose but also on actual drug exposure and sustained adherence.
  • Pharmacokinetic and adherence data can help explain variability in treatment response.
  • Long-term studies should assess outcomes beyond disease activity, including cardiovascular and other organ-related complications.
  • Real-world evidence can uncover additional value from established therapies and inform the design of future prospective trials.
  • Patient education and point-of-care monitoring may themselves become meaningful components of treatment optimization.

This is a strong example of how clinical research can move an established medicine toward more personalized, measurable, and outcomes-focused care.”

Title: Adhering to Common Lupus Treatment Lowers Risk of Heart Issues

Authors: Rachel Martin

Gevorg Yaghjyan

Stay updated on all scientific advances with Hemostasis Today.